Want to see BLFS full AI Analyst Report?
BLFS Stock Chart & Stats
$29.98
-$0.79(-2.57%)
At close: 4:00 PM EDT
$29.98
-$0.79(-2.57%)
Day’s Range― - ―
52-Week Range$17.86 - $33.14
Previous CloseN/A
Volume2.61M
Average Volume (3M)363.00K
Market Cap
$1.53B
Enterprise Value$873.51
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$14.86M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 06, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding48,924,156
10 Day Avg. Volume392,925
30 Day Avg. Volume363,004
Financial Highlights & Ratios
PEG Ratio2.24
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio2.78K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.00Price Target Upside3.40% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)0.15
Revenue Forecast (FY)$113.99M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsMid-60% gross margins are a durable structural advantage in biopreservation consumables and equipment. High unit economics provide pricing power and the capacity to absorb R&D and SG&A, supporting reinvestment, margin resilience across cycles, and long-term cash generation as volume scales.
Market Leadership In BPMDominant position in biopreservation media (BPM) creates durable demand as cell and gene therapy programs commercialize. High embedment in approved therapies and late-stage trials raises switching costs, improves visibility into recurring consumable revenue, and underpins long-term organic growth.
Conservative Balance Sheet / LiquiditySubstantial cash holdings and modest debt provide strategic optionality: funds can support selective M&A, COGS remediation, and working capital during R&D or validation cycles. Low leverage preserves financial flexibility to execute longer-term commercial initiatives without refinancing pressure.
Bears Say
Customer & Product ConcentrationHeavy dependence on a single product family and a small set of customers concentrates revenue risk. Loss or slower ordering by a major customer, or slower program commercialization, would materially impact top line and recurring consumables demand, increasing volatility in multi-quarter horizons.
Manufacturing Yield Issues (bags)Persisting bag yield and scrap problems directly compress gross margins and raise per-unit costs. Until manufacturing yield is fixed and inventories flow through, margin recovery is delayed, reducing operating leverage and constraining durable profitability even if revenues continue to grow.
Long Validation Cycles For New ProductsBiopharma validation timelines are structural: CryoCase, PanTHERA and other launches require lengthy customer validations. This slows cross-sell realization and postpones higher per-dose revenue, meaning anticipated margin and revenue benefits may take many quarters to materialize.
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $17.86 and its highest was $33.14 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.53B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on May 07, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.017 by $0.003.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is 0.03.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 48,924,156 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of $0.02 in its last earnings report, beating expectations of $0.017. Following the earnings report the stock price went down -4.671%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$31.00 (3.40% Upside)
$31.00 (3.40% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 61.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.46%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
BLFS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive growth story highlighted by strong top-line performance (Q1 revenue +25%), improved profitability in absolute dollars (adjusted EBITDA up ~15%, GAAP net income positive), clear market leadership in BPM with robust pipeline visibility, and reaffirmed full-year guidance. Key operational challenges—most notably bag yield/scrap issues that compressed gross margin and adjusted EBITDA margin, rising operating expenses tied to R&D and severance, short-term cash/working capital pressures, and customer/product concentration—represent meaningful near-term risks but are described as manageable and temporary by management. Given the combination of durable demand drivers, strategic initiatives (product launches, cross-sell opportunities) and a solid balance sheet, the positive growth and leadership signals outweigh the transitory operational headwinds in management's view.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services

BLFS Stock 12 Month Forecast
Average Price Target
$31.00
▲(3.40% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
13.72% Insiders
33.10% Mutual Funds
3.48% Other Institutional Investors
31.20% Public Companies and
Individual Investors










